TNGX · Tango Therapeutics, Inc.
$26.65
-0.07 (-0.26%)
At close · Jul 28
Market Cap
$3.85B
Shares
144.65M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-06-23 | 2026-06-19 | |
| 8-K | 2026-06-10 | 2026-06-09 | |
| 8-K | 2026-06-08 | — | |
| 8-K | 2026-06-04 | — | |
| 10-Q | 2026-05-13 | 2026-03-31 | |
| 8-K | 2026-05-13 | — | |
| 8-K | 2026-05-08 | 2026-05-07 | |
| DEF 14A | 2026-04-17 | 2026-04-16 | |
| 8-K | 2026-04-15 | 2026-04-10 | |
| 8-K | 2026-03-05 | — | |
| 10-K | 2026-03-05 | 2025-12-31 | |
| 8-K | 2026-01-08 | 2026-01-07 | |
| 8-K | 2026-01-05 | 2026-01-02 | |
| 8-K | 2025-11-21 | 2025-11-18 | |
| 10-Q | 2025-11-04 | 2025-09-30 | |
| 8-K | 2025-11-04 | — | |
| 8-K | 2025-10-24 | 2025-10-23 | |
| 8-K | 2025-10-23 | — | |
| 8-K | 2025-08-25 | 2025-08-21 | |
| 10-Q | 2025-08-05 | 2025-06-30 | |
| 8-K | 2025-08-05 | — | |
| 8-K | 2025-06-06 | 2025-06-05 | |
| 8-K | 2025-05-12 | — | |
| 10-Q | 2025-05-12 | 2025-03-31 | |
| DEF 14A | 2025-04-21 | — | |
| 8-K | 2025-02-27 | 2022-08-10 | |
| 10-K | 2025-02-27 | 2024-12-31 | |
| 8-K | 2025-01-13 | — | |
| 10-Q | 2024-11-06 | 2024-09-30 | |
| 8-K | 2024-11-06 | — | |
| 10-Q | 2024-08-07 | 2024-06-30 | |
| 8-K | 2024-08-07 | — | |
| 8-K | 2024-06-06 | 2024-06-05 | |
| 8-K | 2024-05-23 | — | |
| 8-K | 2024-05-08 | — | |
| 10-Q | 2024-05-08 | 2024-03-31 | |
| DEF 14A | 2024-04-29 | 2024-12-31 | |
| 8-K | 2024-03-18 | — | |
| 10-K | 2024-03-18 | 2023-12-31 | |
| 8-K | 2024-02-07 | — | |
| 10-Q | 2023-11-08 | 2023-09-30 | |
| 8-K | 2023-11-08 | — | |
| 8-K | 2023-08-30 | 2023-08-28 | |
| 8-K | 2023-08-10 | — | |
| 10-Q | 2023-08-07 | 2023-06-30 | |
| 8-K | 2023-08-07 | 2023-08-03 | |
| 8-K | 2023-06-07 | 2023-06-06 | |
| 10-Q | 2023-05-09 | 2023-03-31 | |
| 8-K | 2023-05-09 | — | |
| DEF 14A | 2023-04-24 | 2023-06-06 |
Showing 1–50 of 74 filings
Key facts
CIK
1819133
CUSIP
87583X109
13F (30d)
24 filings
24 filers
Visit website
Investor relations